Maynard Um
-
-
-
-
-
-
-
AbCellera Biologics (ABCL) PT Raised to $8 at Stifel on Positive Data for ABCL635
-
-
-
-
-
-
-
Which healthcare stocks are at risk from AI and which to buy
-
-
-
-
-
-
-
AbCellera (ABCL) Cleared to Initiate a Phase 1 Clinical Trial of ABCL575 in Canada
-
-
-
-
-
-
-
AbCellera (ABCL) reported revenue at $5.1 million
-
-
-
-
-
-
-
AbCellera (ABCL) and Lilly Expand Collaboration to Develop Antibody Medicines
-
423,042 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

